Phase 2 trial design in neuro-oncology revisited: A report from the RANO group

Evanthia Galanis, Wenting Wu, Timothy Cloughesy, Kathleen Lamborn, Bhupinder Mann, Patrick Y. Wen, David A. Reardon, Wolfgang Wick, David Macdonald, Terri S. Armstrong, Michael Weller, Michael Vogelbaum, Howard Colman, Daniel J. Sargent, Martin J. van den Bent, Mark Gilbert, Susan Chang

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Advances in the management of gliomas, including the approval of agents such as temozolomide and bevacizumab, have created an evolving therapeutic landscape in glioma treatment, thus affecting our ability to reliably use historical controls to comparatively assess the activity of new therapies. Furthermore, the increasing availability of novel, targeted agents-which are competing for a small patient population, in view of the low incidence of primary brain tumours-draws attention to the need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously transition the most promising of these drugs or combinations to potentially practice-changing phase 3 trials. In this report from the Response Assessment in Neurooncology (RANO) group, we review phase 2 trial designs that can address these challenges and capitalise on scientific and clinical advances in brain tumour treatment in neuro-oncology to accelerate and optimise the selection of drugs deserving further testing in phase 3 trials. Although there is still a small role for single-arm and non-comparative phase 2 designs, emphasis is placed on the potential role that comparative randomised phase 2 designs-such as screening designs, selection designs, discontinuation designs, and adaptive designs, including seamless phase 2/3 designs-can have. The rational incorporation of these designs, as determined by the specific clinical setting and the trial's endpoints or goals, has the potential to substantially advance new drug development in neuro-oncology.

Original languageEnglish (US)
JournalThe Lancet Oncology
Volume13
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

temozolomide
Brain Neoplasms
Glioma
Drug Combinations
Therapeutics
Pharmaceutical Preparations
Clinical Trials
Incidence
Population
Bevacizumab

ASJC Scopus subject areas

  • Oncology

Cite this

Phase 2 trial design in neuro-oncology revisited : A report from the RANO group. / Galanis, Evanthia; Wu, Wenting; Cloughesy, Timothy; Lamborn, Kathleen; Mann, Bhupinder; Wen, Patrick Y.; Reardon, David A.; Wick, Wolfgang; Macdonald, David; Armstrong, Terri S.; Weller, Michael; Vogelbaum, Michael; Colman, Howard; Sargent, Daniel J.; van den Bent, Martin J.; Gilbert, Mark; Chang, Susan.

In: The Lancet Oncology, Vol. 13, No. 5, 05.2012.

Research output: Contribution to journalArticle

Galanis, E, Wu, W, Cloughesy, T, Lamborn, K, Mann, B, Wen, PY, Reardon, DA, Wick, W, Macdonald, D, Armstrong, TS, Weller, M, Vogelbaum, M, Colman, H, Sargent, DJ, van den Bent, MJ, Gilbert, M & Chang, S 2012, 'Phase 2 trial design in neuro-oncology revisited: A report from the RANO group', The Lancet Oncology, vol. 13, no. 5. https://doi.org/10.1016/S1470-2045(11)70406-5
Galanis, Evanthia ; Wu, Wenting ; Cloughesy, Timothy ; Lamborn, Kathleen ; Mann, Bhupinder ; Wen, Patrick Y. ; Reardon, David A. ; Wick, Wolfgang ; Macdonald, David ; Armstrong, Terri S. ; Weller, Michael ; Vogelbaum, Michael ; Colman, Howard ; Sargent, Daniel J. ; van den Bent, Martin J. ; Gilbert, Mark ; Chang, Susan. / Phase 2 trial design in neuro-oncology revisited : A report from the RANO group. In: The Lancet Oncology. 2012 ; Vol. 13, No. 5.
@article{528d8a6fef2148ed83e0e6418f554273,
title = "Phase 2 trial design in neuro-oncology revisited: A report from the RANO group",
abstract = "Advances in the management of gliomas, including the approval of agents such as temozolomide and bevacizumab, have created an evolving therapeutic landscape in glioma treatment, thus affecting our ability to reliably use historical controls to comparatively assess the activity of new therapies. Furthermore, the increasing availability of novel, targeted agents-which are competing for a small patient population, in view of the low incidence of primary brain tumours-draws attention to the need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously transition the most promising of these drugs or combinations to potentially practice-changing phase 3 trials. In this report from the Response Assessment in Neurooncology (RANO) group, we review phase 2 trial designs that can address these challenges and capitalise on scientific and clinical advances in brain tumour treatment in neuro-oncology to accelerate and optimise the selection of drugs deserving further testing in phase 3 trials. Although there is still a small role for single-arm and non-comparative phase 2 designs, emphasis is placed on the potential role that comparative randomised phase 2 designs-such as screening designs, selection designs, discontinuation designs, and adaptive designs, including seamless phase 2/3 designs-can have. The rational incorporation of these designs, as determined by the specific clinical setting and the trial's endpoints or goals, has the potential to substantially advance new drug development in neuro-oncology.",
author = "Evanthia Galanis and Wenting Wu and Timothy Cloughesy and Kathleen Lamborn and Bhupinder Mann and Wen, {Patrick Y.} and Reardon, {David A.} and Wolfgang Wick and David Macdonald and Armstrong, {Terri S.} and Michael Weller and Michael Vogelbaum and Howard Colman and Sargent, {Daniel J.} and {van den Bent}, {Martin J.} and Mark Gilbert and Susan Chang",
year = "2012",
month = "5",
doi = "10.1016/S1470-2045(11)70406-5",
language = "English (US)",
volume = "13",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - Phase 2 trial design in neuro-oncology revisited

T2 - A report from the RANO group

AU - Galanis, Evanthia

AU - Wu, Wenting

AU - Cloughesy, Timothy

AU - Lamborn, Kathleen

AU - Mann, Bhupinder

AU - Wen, Patrick Y.

AU - Reardon, David A.

AU - Wick, Wolfgang

AU - Macdonald, David

AU - Armstrong, Terri S.

AU - Weller, Michael

AU - Vogelbaum, Michael

AU - Colman, Howard

AU - Sargent, Daniel J.

AU - van den Bent, Martin J.

AU - Gilbert, Mark

AU - Chang, Susan

PY - 2012/5

Y1 - 2012/5

N2 - Advances in the management of gliomas, including the approval of agents such as temozolomide and bevacizumab, have created an evolving therapeutic landscape in glioma treatment, thus affecting our ability to reliably use historical controls to comparatively assess the activity of new therapies. Furthermore, the increasing availability of novel, targeted agents-which are competing for a small patient population, in view of the low incidence of primary brain tumours-draws attention to the need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously transition the most promising of these drugs or combinations to potentially practice-changing phase 3 trials. In this report from the Response Assessment in Neurooncology (RANO) group, we review phase 2 trial designs that can address these challenges and capitalise on scientific and clinical advances in brain tumour treatment in neuro-oncology to accelerate and optimise the selection of drugs deserving further testing in phase 3 trials. Although there is still a small role for single-arm and non-comparative phase 2 designs, emphasis is placed on the potential role that comparative randomised phase 2 designs-such as screening designs, selection designs, discontinuation designs, and adaptive designs, including seamless phase 2/3 designs-can have. The rational incorporation of these designs, as determined by the specific clinical setting and the trial's endpoints or goals, has the potential to substantially advance new drug development in neuro-oncology.

AB - Advances in the management of gliomas, including the approval of agents such as temozolomide and bevacizumab, have created an evolving therapeutic landscape in glioma treatment, thus affecting our ability to reliably use historical controls to comparatively assess the activity of new therapies. Furthermore, the increasing availability of novel, targeted agents-which are competing for a small patient population, in view of the low incidence of primary brain tumours-draws attention to the need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously transition the most promising of these drugs or combinations to potentially practice-changing phase 3 trials. In this report from the Response Assessment in Neurooncology (RANO) group, we review phase 2 trial designs that can address these challenges and capitalise on scientific and clinical advances in brain tumour treatment in neuro-oncology to accelerate and optimise the selection of drugs deserving further testing in phase 3 trials. Although there is still a small role for single-arm and non-comparative phase 2 designs, emphasis is placed on the potential role that comparative randomised phase 2 designs-such as screening designs, selection designs, discontinuation designs, and adaptive designs, including seamless phase 2/3 designs-can have. The rational incorporation of these designs, as determined by the specific clinical setting and the trial's endpoints or goals, has the potential to substantially advance new drug development in neuro-oncology.

UR - http://www.scopus.com/inward/record.url?scp=84860487114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860487114&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(11)70406-5

DO - 10.1016/S1470-2045(11)70406-5

M3 - Article

C2 - 22554547

AN - SCOPUS:84860487114

VL - 13

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 5

ER -